Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities
K Venkatakrishnan, LE Friberg… - Clinical …, 2015 - Wiley Online Library
Despite advances in biomedical research that have deepened our understanding of cancer
hallmarks, resulting in the discovery and development of targeted therapies, the success …
hallmarks, resulting in the discovery and development of targeted therapies, the success …
Platelet immunology in fungal infections
C Speth, G Rambach… - Thrombosis and …, 2014 - thieme-connect.com
Up to date, perception of platelets has changed from key players in coagulation to
multitaskers within the immune network, connecting its most diverse elements and crucially …
multitaskers within the immune network, connecting its most diverse elements and crucially …
Reinforcement learning and Bayesian data assimilation for model‐informed precision dosing in oncology
Abstract Model‐informed precision dosing (MIPD) using therapeutic drug/biomarker
monitoring offers the opportunity to significantly improve the efficacy and safety of drug …
monitoring offers the opportunity to significantly improve the efficacy and safety of drug …
Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children
Purpose: To evaluate the best method for dosing busulfan in children, we retrospectively
analyzed two different data sets from three different dosing regimens by means of population …
analyzed two different data sets from three different dosing regimens by means of population …
Characterization of endogenous G-CSF and the inverse correlation to chemotherapy-induced neutropenia in patients with breast cancer using population modeling
AL Quartino, MO Karlsson, H Lindman… - Pharmaceutical …, 2014 - Springer
Purpose Neutropenia is a severe adverse-event of chemotherapeutics. Neutrophils (ANC)
are mainly regulated by granulocyte colony stimulating factor (G-CSF). The aim was to …
are mainly regulated by granulocyte colony stimulating factor (G-CSF). The aim was to …
A continued learning approach for model‐informed precision dosing: updating models in clinical practice
Abstract Model‐informed precision dosing (MIPD) is a quantitative dosing framework that
combines prior knowledge on the drug‐disease‐patient system with patient data from …
combines prior knowledge on the drug‐disease‐patient system with patient data from …
A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model
AL Quartino, LE Friberg, MO Karlsson - Investigational new drugs, 2012 - Springer
Purpose To improve the predictive capacity of a semi-mechanistic myelosuppression model
for neutrophils as the model have shown to over-predict the nadir of neutrophils and …
for neutrophils as the model have shown to over-predict the nadir of neutrophils and …
Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring
Purpose To investigate whether a more frequent monitoring of the absolute neutrophil
counts (ANC) during myelosuppressive chemotherapy, together with model-based …
counts (ANC) during myelosuppressive chemotherapy, together with model-based …
Model‐based neutrophil‐guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information
JE Wallin, LE Friberg… - Basic & clinical …, 2010 - Wiley Online Library
One of the most employed approaches to reduce severe neutropenia following anticancer
drug regimens is to reduce the consecutive dose in fixed steps, commonly by 25%. Another …
drug regimens is to reduce the consecutive dose in fixed steps, commonly by 25%. Another …
Understanding hematological toxicities using mathematical modeling
Balancing antitumor efficacy with toxicity is a significant challenge, and drug‐induced
myelosuppression is a common dose‐limiting toxicity of cancer treatments. Mathematical …
myelosuppression is a common dose‐limiting toxicity of cancer treatments. Mathematical …